Deregulated expression of fibroblast growth factor receptors (FGFRs) and their ligands plays critical roles in tumorigenesis. The gene expression of an alternatively spliced isoforms of FGFR3, FGFR3IIIc, was analyzed by RT-PCR in samples from patients with esophageal carcinoma (EC), including esophageal squamous cell carcinoma (ESCC) and adenocarcinoma (EAC). The incidence of FGFR3IIIc was higher in EC [12/16 (75%); p=0.073] than in non-cancerous mucosa (NCM) [6/16 (38%)]. Indeed, an immunohistochemical analysis of early-stage ESCC showed that carcinoma cells expressing FGFR3IIIc stained positively with SCC-112, a tumor marker, and Ki67, a cell proliferation marker, suggesting that the expression of FGFR3IIIc promotes cell proliferation. We used EC-GI-10 cells endogenously expressing FGFR3IIIc as a model of ESCC to provide mechanistic insight into the role of FGFR3IIIc in ESCC. The knockdown of endogenous FGFR3 using siRNA treatment significantly abrogated cell proliferation and the overexpression of FGFR3IIIc in cells with enhanced cell proliferation. EC-GI-10 cells and ESCC from patients with EC showed endogenous expression of FGF2, a specific ligand for FGFR3IIIc, suggesting that the upregulated expression of FGFR3IIIc may create autocrine FGF signaling in ESCC. Taken together, FGFR3IIIc may have the potential to be an early-stage tumor marker and a molecular target for ESCC therapy. (J Histochem Cytochem 64:7-17, 2016) 
Introduction
The human genome contains 22 genes that code for fibroblast growth factors (FGFs). FGFs induce cell proliferation, differentiation and migration by binding to specific receptors (Basilico and Moscatelli 1992; Tanaka et al. 1992; Yamasaki et al. 1996) . Fibroblast growth factor receptors (FGFRs) are encoded by four genes. The consensus structure of FGFRs consists of three Ig-like domains in the extracellular region, a single spanning transmembrane domain, and a split tyrosine kinase domain in the cytoplasmic region (Johnson and Williams 1993) . When FGF binds to FGFRs, the tyrosine kinase domain in the cytoplasmic region of the receptors is activated and generates signals through, for example, the Ras-MAPK, PI3K-Akt and PLC-γ-PKC pathways to induce cell proliferation, differentiation, migration 616161J HCXXX10.1369/0022155415616161Expression of FGFR3IIIc in Esophageal CarcinomaUeno et al. research-article2015 and oncogenesis (Powers et al. 2000) . FGFR3 in particular is known to harbor oncogenic activity in several types of cancers. Malignant progression by the enhanced expression or variation in FGFR3 has been reported for bladder cancer, colon cancer and multiple myeloma (Gomez-Roman et al. 2005; Qing et al. 2009; Haugsten et al. 2010; Sonvilla et al. 2010; Wesche et al. 2011) . In recent studies, cell proliferation in these cancers was shown to be suppressed by a neutralizing antibody against FGFR3 or a tyrosine kinase inhibitor of FGFR3, indicating that the activation of FGFR3 contributes to the malignant progression of cancers (Tomlinson et al. 2007; Qing et al. 2009; Miyake et al. 2010) .
In Japan, approximately 90% of esophageal carcinoma (EC) is esophageal squamous cell carcinoma (ESCC) (Shigeoka and Shiozaki 2004) , and the overall death rate in the general population for patients with EC has been reported to be 15.7 per 100,000 for men and a 2.6 per 100,000 for women. The prognosis of patients with EC is known to be poor, with the 5-year relative survival rates remaining at approximately 30%. This rate is lower than those for patients with other gastrointestinal cancers such as stomach, colon and rectal cancers (Satoh and Sakata 2009; Wakao et al. 2013) .
Two alternatively spliced isoforms of FGFR3 possess an alternative sequence for the C-terminal half of the third Ig domain (IgIII), encoded by a separate 5'-exon IIIa and 3'-exon, either IIIb or IIIc, which determines FGF specificity. FGFR3IIIc has been shown to have a broader ligand spectrum (FGF1, 2, 4, 5, 6, 8, 9, 16, 17, 18, 19, 20, 21, and 23 ) than that of FGFR3IIIb (FGF1, 9, 16, and 20) (Ornitz et al. 1996; Kanai et al. 1997; Zhang et al. 2006) The expression of FGFR isoforms is temporally and spatially regulated in embryos as well as in normal adult organs. The expression of FGFR3IIIb has been associated with an epithelial lineage, whereas FGFR3IIIc is predominantly expressed in non-epithelial cells and tissues (Murgue et al. 1994) . Ligands are produced in either epithelial or mesenchymal tissues and generally activate receptors of the opposite tissue specificity. Pathological states can result from a breakdown in binding specificity, as is common in the types of cancers that display an overexpression of FGFs (Beenken and Mohammadi 2009) . For example, in colorectal cancer, FGFR3IIIc expression is upregulated but FGFR3IIIb is downregulated with increasing tumor stage, resulting that a ratio of IIIc/IIIb expression that increases with increasing stage (Sonvilla et al. 2010) . FGF18, a specific ligand for FGFR3IIIc, is also upregulated in colorectal cancer (Shimokawa et al. 2003 ), suggesting that FGFR3IIIc imparts changes such as cell proliferation and migration by mediating the effects of FGF18 effects in colorectal cancer (Sonvilla et al. 2010) . In EC, a previous study demonstrated that the expression of FGF2, a specific ligand for FGFR3IIIc, is upregulated in the patients with poor prognosis (Barclay et al. 2005 ).
In the present study, we assessed the expression of FGFR3 isoforms in EC, including ESCC and the neighboring noncancerous mucosa (NCM) by RT-PCR and immunohistochemical analysis, and found that cells from patients with early-stage EC express FGFR3IIIc. In an in vitro study, lentivirus-induced FGFR3IIIc overexpression in EC-GI-10 cells promoted the cell proliferative activity. These results suggest that FGFR3IIIc may have the potential to be an early-stage tumor marker and a molecular target for ESCC therapy.
Materials & Methods

Tissue Specimens
Fresh samples of EC and NCM for RT-PCR analysis were obtained from patients undergoing surgery for EC at Kitano Hospital in Osaka, Japan, after obtaining informed consent from each patient enrolled in the study (Table 1) . Formalinfixed, paraffin-embedded tissue sections of ESCC for immunohistochemical analysis were retrieved from the pathology files of Shinshu University Hospital in Matsumoto, Japan ( Table 2) . The study plan, including the use of human samples, was approved by the Ethics Committees of Kitano Hospital, Shinshu University School of Medicine, and Kyoto Sangyo University. Moreover, the study was conducted in full conformity with the current revision of the Declaration of Helsinki.
RNA Extraction
Total RNA was extracted from tissue specimens using ISOGEN (Nippon Gene; Tokyo, Japan) according to the manufacturer's protocol.
RT-PCR Analysis
First-strand cDNA was synthesized using the Superscript First-Strand Synthesis System for RT-PCR (#11904-018; Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. PCR for the expression of GAPDH, FGFRs and FGF2 in EC and neighboring NCM from patients and EC-GI-10 cells was performed using TaqDNA polymerase (Promega; Fitchburg, WI) or Gotaq® Green Master Mix (Promega). The primer sequences are listed in Table 3 .
Antigen Adsorption
A recombinant human FGFR3IIIc Fc chimera (#766-FR-050, lot.CWZ0713081; R&D Systems, Minneapolis, MN), which contains the extracellular region of FGFR3IIIc and Fc region of human IgG 1 , was incubated with anti-FGFR3IIIc antibody (cat#MAB7662, lot.GHK0411041; R&D Systems) in PBS containing 0.1% Tween-20, 3% BSA without γ-globulin (Wako; Kyoto, Japan), and 3% horse serum for 1 hr at room temperature. The mixture was then used for western blot analysis and immunohistochemistry as an antigen-adsorbed primary antibody. The concentration of the recombinant human FGFR3IIIc Fc chimera was 10-fold higher than that of the anti-FGFR3IIIc antibody.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections from ESCC patients were deparaffinized and rehydrated in graded alcohols. Tissue sections were incubated with 10 mM citrate buffer, pH 6.0, at 95°C for 20 min for epitope retrieval. The sections were blocked with PBS containing 0.1% Tween-20, 3% BSA without γ-globulin (Wako), and 3% horse serum for 30 min at room temperature to eliminate non-specific binding. In immunoperoxidase staining, the sections were treated with 3% hydrogen peroxide for 12 min at room temperature before blocking. The sections were incubated with a monoclonal anti-FGFR3IIIc antibody (#MAB7662, lot GHK0411041, R&D Systems; 1:25 dilution), rabbit anti-SCC-112 antibody (#A3000-088A, lot A300-088A-1, Bethyl Laboratories, Inc., Montgomery, TX; 1:100 dilution) or monoclonal anti-Ki67 antibody (#M7240, lot 00040373, Agilent Technologies, Santa Clara, CA; 1:100 dilution) at 4°C overnight. The sections were incubated with biotinylated anti-mouse IgG (Vector Laboratories, Burlingame, CA; 1:50 dilution) or biotinylated anti-rabbit IgG (Invitrogen, Carlsbad, CA; 1:50 dilution) for 1 hr at room temperature. The sections were incubated with an Alexa Fluor 488-conjugated secondary antibody and Alexa Fluor 594-conjugated streptavidin (Life Technologies, Rockville, MD; 1:100 dilution) for 1 hr at room temperature. The nucleus was stained by 4', 6-diamidino-2-phenylindole (DAPI; Invitrogen).
Regarding immunoperoxidase staining, sections were stained by using the Vectastain Elite ABC kit (#PK-6100; Vector Laboratories) and Peroxidase Substrate kit DAB (PK-4100; Vector Laboratories) according to the manufacturer's protocol. Sections were counterstained using Mayer's hematoxylin solution (Wako). Microphotographs were taken with an Eclipse E800 (Nikon; Tokyo, Japan) or a DM5500 Q (Leica Microsystems; Wetzlar, Germany).
Cell Lines
The EC-GI-10 ESCC line, which was established from Japanese male (65-year-old ESCC patient), was obtained from the RIKEN cell bank (Tsukuba, Japan) and cultured in Dulbecco's Modified Eagle's Medium (Nissui; Tokyo, Japan) containing 10% fetal bovine serum (GE Healthcare; Little Chalfont, UK), 4.5 g/L glucose, 2 mM L-glutamine, 50 U/ml penicillin, and 50 μg/ml streptomycin (Sato et al. 1987) . The authenticity of the EC-GI-10 cells used in this study was validated by the STR-PCR method performed by the RIKEN cell bank, where the cells were tested for mycoplasma by DNA staining and PCR and validated as negative. We also sent the cells to the ICLAS Monitoring Center RT-PCR analysis E1 (Kawasaki, Japan) to test for mycoplasma infection by PCR and they were confirmed to be negative. HEK293T cells were purchased from ATCC (Manassas, VA) and cultured in DMEM supplemented with 10% FBS.
Lentivirus Construction and Induction
Human FGFR3IIIb and FGFR3IIIc cDNAs were amplified by PCR using FGFR3IIIb or FGFR3IIIc specific primers and subcloned into the pHAGE lentiviral backbone vector at NotI/BamHI sites. FGFR3 primer pairs were 5'-GGGGATCCGGCCCTTCACGTCCGCGAGCCCC-3' and 5'-GGGCGGCCGCGCCGCCATGGGCGCCCCTGC CTGCGCC-3'. EGFP in the pHAGE lentiviral backbone vector was generously provided by Dr. A. Mammoto (Boston Children's Hospital). Each FGFR3IIIb, FGFR3IIIc, and EGFP in the pHAGE lentiviral backbone vector was co-transfected with the helper plasmids (tat, rev, gag-pol and VSV-G) into HEK293 cells, as described previously (Mostoslavsky et al. 2005; Mammoto et al. 2007; Shimizu et al. 2008 ). Viral supernatants were assembled and concentrated at 38,000 × g for 1.5 hr at 4°C. The virus was infected with 10 μg/ml of polybrene (Millipore; Billerica, MA) to express FGFR3IIIb, FGFR3IIIc, or EGFP in EC-GI-10 cells or HEK293T cells.
Design of siRNAs
We designed the original siRNA sequences that targeted the 3'-UTR in human FGFR3 mRNA sequences (FGFR3 siRNA) to knock down the endogenous FGFR3 in EC-GI-10 cells, since the lentivirus vector encoding FGFR3IIIb or FGFR3IIIc does not include the 3'-UTR. The siRNA sequences were designed by the Whitehead siRNA Selection Web Server (Yuan et al. 2004) . We validated that the siRNA knocked down the endogenous FGFR3 in EC-GI-10 cells, but not lentivirus expressed FGFR3IIIb or FGFR3IIIc (Fig. 4B ). siRNAs were synthesized by Japan Bio Services Co. (Saitama, Japan). The FGFR3 siRNA pairs were 5'-GAUGCUGUGUAUAUGGUAUTT-3' and 5'-AUACCAUAUACACAGCAUCTT-3'. The sicontrol pairs were 5'-UGGUUUACAUGUCGACUAATT-3' and 5'-UUAGUCGACAUGUAAACCATT-3'.
Cell Proliferation Assay
EC-GI-10 cells (3 × 10 5 cells/4 ml) were seeded into a 6-cm dish. Cells were then transfected with 3 nM of FGFR3 siRNA or control siRNA (sicontrol) by siLentFect TM Lipid (Bio-Rad; Hercules, CA) according to the manufacturer's protocols. After 24 hr, the cells were then infected with a lentivirus encoding FGFR3IIIb, FGFR3IIIc or EGFP with 10 μg/ml of polybrene (Millipore). After 24 h, these cells were plated onto a well (6 x 10 3 cells/500 μl) in a 24-well plate with DMEM containing 1% fetal bovine serum, 4.5 g/L glucose, 2 mM L-glutamine, 50 U/ml penicillin, and 50 μg/ml streptomycin. After 5 days in culture, the cells were collected by trypsinization and the number of cells counted with a Coulter Counter ZM cell counter (Beckman Coulter Inc., Brea, CA).
Immunocytochemistry
HEK293T cells (3 × 10 5 cells/4 ml) were seeded into a 6-cm dish. After 24 hr, the cells were infected with a lentivirus Table 3 . PCR Primer Sequences.
Gene Name Sequence
FGFR1IIIb
encoding either FGFR3IIIb or FGFR3IIIc with 10 μg/ml of polybrene (Millipore). After a further 24 hr, these cells were lifted and plated into the wells (5 × 10 4 cells/100 μl) of a 96-well plate coated with 2.7 μg/ml of poly-D-lysine hydrobromide (Sigma-Aldrich; St. Louis, MO). EC-GI-10 cells were plated into a well (2 × 10 5 cells/2 ml) of a 6-well plate. After 24 hr, the cells were fixed with a 4% paraformaldehyde phosphate-buffered solution (Wako) for 20 min, and were blocked with PBS containing 0.1% Tween-20, 3% BSA without γ-globulin (Wako), and 3% horse serum for 30 min at room temperature. The cells were incubated with a monoclonal anti-FGFR3IIIc antibody (#MAB7662, lot. GHK0411041, R&D Systems; 1:50 dilution) or rabbit anti-SCC-112 antibody (#A3000-088A, lot. A300-088A-1, Bethyl Laboratories, Inc.; 1:100 dilution) at 4°C overnight. EC-GI-10 cells were treated with 0.2% Triton X-100 for 5 min at room temperature before blocking. The cells were incubated with an Alexa Fluor 594-conjugated secondary antibody (Life Technologies; 1:100 dilution) for 1 hr at room temperature. The nuclei were stained with DAPI (Invitrogen) in 0.2% Triton X-100. Microphotographs were taken with an ECLIPSE Ti-U (Nikon).
Western Blot Analysis
EC-GI-10 cells were lysed with a cold RIPA buffer containing 50 mM Tris-HCl, pH 7.4, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 100 mM NaCl and 1% protease inhibitor (Nacalai Tesque; Kyoto, Japan). The cell lysates were electrophoresed through 7.5% polyacrylamide gels and transferred to PVDF membranes (Immobilon-P; Millipore), and were analyzed by immunoblotting with the monoclonal anti-β-actin antibody (Sigma-Aldrich; 1:2000 dilution), anti-FGFR3 antibody (C-15) (Santa Cruz Biotechnology, Dallas, TX; 1:2000 dilution) and monoclonal anti-FGFR3IIIc antibody (cat#MAB7662, lot.GHK411041, R&D Systems; 1:500 dilution). After incubation with primary antibodies overnight at 4°C, the membrane was incubated with peroxidase-conjugated donkey anti-mouse IgG (#715-035-150, lot. 120343, Jackson ImmunoResearch, Suffolk, UK; 1:5000 dilution) or peroxidase-conjugated donkey anti-rabbit IgG (#711-035-152, lot. 117895, Jackson ImmunoResearch; 1:5000 dilution) for 1 hr at room temperature. The blots were treated with chemiluminescence substrate solution (#34080, Thermo Fisher Scientific; Waltham, MA) according to the manufacturer's protocol and exposed to LAS-4000 mini (Fujifilm Co.; Tokyo, Japan) to reveal immunoreactive bands.
Statistical Analysis
Data are presented as the mean ± S.E.M. A one-way analysis of variance (ANOVA) followed by post-hoc testing was performed. 
Results
Enhanced Expression of FGFR3IIIc in Human EC
We obtained primary EC and neighboring NCM samples from patients (n=16) Table 4 ). The incidence of FGFR3IIIc expression was 2-fold higher in EC than in NCM. However, no difference was observed in the incidence of FGFR3IIIb expression between EC (12/16, 75%; p=1.000) and NCM (11/16, 69%) regions (Table 4 ). Figure 1 shows the expression of FGFR3IIIb and FGFR3IIIc in 16 ESCC specimens (E1-E16). Although the expression of the other FGFRs (FGFR1, FGFR2, and FGFR4) was analyzed in both NCM and EC, no differences were noted in the incidence of expression between ESCC and NCM (Supplemental Fig. S1 ).
FGFR3IIIc Has the Potential to be a New Biomarker of ESCC from the Early Stage
FGFR3IIIc was expressed in the early stage of ESCC (Table  4 ). An immunohistochemical analysis of ESCC from patients diagnosed with TNM classification stage 0 showed that the cells expressing SCC-112, a tumor marker, were also positively stained for FGFR3IIIc (Zheng et al. 2008 ) ( Fig. 2A, parts d , e, f: white arrows). Neither SCC-112-nor FGFR3IIIc-positive cells were detected in normal esophageal epithelium cells ( Fig. 2A, parts a, b, c) . Most EC cells (SCC-112 positive) were also positive for Ki-67, a proliferating cell marker (Fig. 2B, parts d , e, f: white arrows). FGFR3IIIc-expressing cells also expressed Ki-67 in serial sections of the specimens (Fig. 2C , parts c, f: white arrows).
These results indicate that the expression of FGFR3IIIc was enhanced in EC cells but not in the normal mucosa or in other types of cells, and that FGFR3IIIc may contribute to signal-enhanced cell proliferation. We further analyzed the expression of FGFR3IIIc in esophageal tissues from other patients diagnosed with TNM classification stage IA that contained both EC cells and normal esophageal epithelium cells (Fig. 3A-3C ). Strong staining for FGFR3IIIc was observed in EC cells ( Fig. 3B : white arrows). Cells positively stained for FGFR3IIIc were distinguishable from negatively stained cells by a clear border, indicating that normal esophageal epithelium cells do not express FGFR3IIIc (Fig. 3B: black arrows) . The FGFR3IIIc-positive area was consistent with the same area of strong staining for SCC-112 in the nuclei on consecutive sections (Fig. 3C: white arrows) , but was not observed in SCC112-negative areas (Fig. 3C: black arrows) . The strong staining of FGFR3IIIc in the EC area ( Fig. 3E and G: white arrows) was also observed in tissue samples from different patients who were diagnosed with TNM classification stage IB (Fig. 3D and 3E ) and stage IIIA ( Fig. 3F and 3G ), but was absent in normal esophageal epithelium areas ( Fig. 3E and 3G: black arrows). Staining of FGFR3IIIc in the EC area was specific, because FGFR3IIIc did not stain with the anti-FGFR3IIIc antibody after pre-adsorption with recombinant human FGFR3IIIc Fc chimera ( Fig. 3H; Supplemental  Fig. S4A and S4B) .
In all ESCC patients, the strong staining of FGFR3IIIc was observed only in EC cells (6/6, 100%) and not in normal esophageal epithelium cells (0/5, 0%) (Table 3) .
These results indicate that FGFR3IIIc has the potential to be a new biomarker for ESCC at the early stage, because the expression of FGFR3IIIc is clearly restricted in EC cells at stage 0 ( Fig. 2A, parts c, and f).
Enhanced Expression of FGFR3IIIc Accelerates Cell Proliferation by Endogenous FGF2
FGFR3IIIc was detected in cells that also expressed Ki-67 in serial sections (Fig. 2C, parts c, f) . These results suggest that the enhanced expression of FGFR3IIIc accelerates cell proliferation in ESCC. To determine whether the expression of FGFR3IIIc contributed to cell proliferation in EC cells, we performed a cell proliferation assay using EC-GI-10 cells as a model of EC cells. EC-GI-10 cells are an ESCC line (Nagoya et al. 2013; Saito et al. 2015 ) that endogenously expresses FGFR3IIIc, FGFR3IIIb, and SCC-112, a tumor marker (Supplemental Fig. S2A and S2B) . To evaluate whether the endogenous expression of FGFR3IIIb and FGFR3IIIc contribute to the proliferation of cells, we knocked down both isoforms using FGFR3 siRNA (siF-GFR3), which targets the 3'-UTR of FGFR3 mRNA. Endogenous FGFR3 protein expression levels were lower in EC-GI-10 cells treated with siFGFR3 (siFGFR3-EC-GI-10 cells) than in cells treated with sicontrol (sicontrol-EC-GI-10 cells) (Fig. 4B) . Cell proliferation was significantly reduced (by 15%) in siFGFR3-EC-GI-10 cells as compared with sicontrol-EC-GI-10 cells, indicating that endogenously expressed FGFR3 in EC-GI-10 cells enhanced cell proliferation. Next, we overexpressed FGFR3IIIc or FGFR3IIIb in Figure 1 . Gene expression of FGFR3 isoforms in esophageal carcinoma (EC) and non-cancerous mucosa (NCM). Total RNA was extracted from the specimens of EC patients. The gene expression of FGFR3 in 16 patients (E1 to E16) was analyzed by RT-PCR. FGFR3IIIc expression was clearly detected in the EC (T; tumor) of 12 patients (E2, E3, E4, E5, E6, E7, E8, E10, E13, E14, E15, and E16) and in the NCM (N; non-tumor) of 6 patients (E1, E3, E10, E13, E14, and E15). FGFR3IIIb expression was clearly detected in the EC (T) of 12 patients and in the NCM (N) of 11 patients. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
siFGFR3-EC-GI-10 cells by lentiviral infection (FGFR3IIIcoverexpressed EC-GI-10 cells and FGFR3IIIb-overexpressed EC-GI-10 cells), and used siFGFR3-EC-GI-10 cells infected with EGFP-lentivirus as a control (EGFP-infected EC-GI-10 cells; Supplemental Fig. S3 ). Cell proliferation was significantly higher (by 1.3-fold) in FGFR3IIIc-overexpressed EC-GI-10 cells than in siFGFR3-EC-GI-10 cells (Fig. 4A) . In contrast, cell proliferation was not enhanced in FGFR3IIIb-overexpressed EC-GI-10 cells over siFGFR3-EC-GI-10 cells (Fig. 4A) . The cell proliferation in EGFPinfected EC-GI-10 cells was significantly lower (by 25%) than that in siFGFR3-EC-GI-10 cells, suggesting that the EGFP protein may reduce cell proliferation or be cytotoxic to the cells in this study (Liu et al. 1999) . A western blot analysis revealed that the expression of FGFR3IIIc in FGFR3IIIc-overexpressed EC-GI-10 cells was similar to that of FGFR3IIIb in FGFR3IIIb-overexpressed EC-GI-10 cells (Fig. 4B) . These results indicate that the strong expression of FGFR3IIIc in ESCC accelerated cell proliferation, whereas that of FGFR3IIIb did not.
FGF2 ligand specifically binds to FGFR3IIIc but not FGFR3IIIb (Chellaiah et al. 1994; Terada 2009 ). FGF2 in EC has been reported to be up-regulated and involved in the poor prognosis of patients (Barclay et al. 2005 ). An RT-PCR analysis was performed in order to confirm whether FGF2 was expressed in parental EC-GI-10 cells. FGF2 was detected in parental EC-GI-10 cells (Fig. 4C ), suggesting that enhancements in cell proliferation by the expression of FGFR3IIIc were induced by endogenous FGF2 via an autocrine pathway.
FGF2 Is Expressed in ESCC and NCM
An RT-PCR analysis was performed to determine whether the expression of FGF2 was higher in ESCC (T) than in NCM (N). No significant difference between was observed in the incidence of FGF2 expression between ESCC (6/7, 86%) and NCM (6/7, 86%) ( Fig. 5) , indicating that the expression of FGF2 did not change between NCM and ESCC.
Discussion
Tumor markers, including the squamous cell carcinomarelated antigen (SCC), carcinoembryonic antigen (CEA), CA19-9, CYFRA, CA125, and mutated p53, are widely used to diagnose EC (Mealy et al. 1996; Song et al. 2009 ). A clinical study demonstrated that human EC markers had low sensitivity for cancer screening, and tumor marker levels of CEA, CA19-9, CA125, and SCC did not correlate with the stage of disease or short-term survival (Mealy et al. 1996) .
The constitutive activation of FGFR3 has been shown to drive malignant progression in multiple myeloma, colorectal cancer, and bladder cancer (Gomez-Roman et al. 2005; Qing et al. 2009; Sonvilla et al. 2010) . A blockade of activated FGFR3, using highly specific antibody-targeting of FGFR3, reduced tumor growth in a t(4;14)-positive multiple myeloma mouse model (Qing et al. 2009 ). An antibody against FGFR3 or the use of PD173074, a selective tyrosine kinase inhibitor of FGFR3, suppressed cell proliferation in human bladder carcinoma and tumor growth in a mouse xenograft model (Gomez-Roman et al. 2005; Qing et al. 2009; Miyake et al. 2010) . The overexpression of FGFR3IIIc induced cell proliferation in colon carcinoma cell lines and tumor growth in a mouse xenograft model (Sonvilla et al. 2010 ). Thus, these findings demonstrate that FGFR3 is tumorigenic.
Although several studies have shown FGFR1 and FGFR2 amplification in ESCC patients (Ishizuka et al. 2002; Kato et al. 2013) , the upregulation of FGFR3 expression in EC has not yet been examined. We herein demonstrate that the expression of FGFR3IIIc was higher in EC regions than in NCM regions. In contrast, the expression of FGFR3IIIb was higher than that of FGFR3IIIc in NCM regions but remained unchanged in EC. In this study, due to the limited number of the patients who underwent curative resection, it was difficult to adjust for known prognostic factors such as age, sex, T and N stages for multivariable and univariable analyses of survival outcome (i.e., overall survival or progression-free survival) based on the expression levels of FGFR3IIIc. An immunohistochemical analysis of ESCC from patients diagnosed as stage 0-defined as high-grade dysplasia by the TNM classification-showed that FGFR3IIIc is restricted to EC cells, indicating that, during the early stages of carcinogenesis, FGFR3IIIc could confer some benefit to enhance the proliferative activities for the progression of malignancy. Indeed, in this study, FGFR3IIIc was detected in EC cells, which also expressed Ki-67. Thus, FGFR3IIIc may be an early-stage tumor marker because the expression of FGFR3IIIc was clearly restricted to stage 0 EC cells. Certain molecular mechanisms associated with carcinogenesis in the esophageal epithelium may upregulate the expression of FGFR3IIIc, but not that of FGFR3IIIb.
SCC-112 has been reported to promote cell proliferation and contributes to tumorigenesis by interacting with p63, a transcription factor (Fessing et al. 2011 ) that affects the survival and proliferative capacity of squamous epithelia and promotes cell cycling (Barbieri et al. 2003; Zheng et al. 2008) . We used SCC-112 as a tumor marker in our experiments, since SCC-112 expression was detected in EC but not in the normal counterpart (Zheng et al. 2008) . In this study, FGFR3IIIc was detected in EC cells that also expressed SCC-112. However, we have yet to establish a functional relationship between FGFR3IIIc and SCC-112.
In the in vitro study, our results showed that the overexpression of FGFR3IIIc, but not that of FGFR3IIIb, enhanced cell proliferation in EC-GI-10 cells. Conversely, the Cell proliferation was significantly lower (by 15%) in EC-GI-10 cells treated with FGFR3 siRNA (siFGFR3) than in EC-GI-10 cells treated with sicontrol (sicontrol) after 5 days in culture. Cell proliferation in FGFR3IIIc-overexpressed siFGFR3-EC-GI-10 cells (FGFR3IIIc) was significantly higher than that in siFGFR3-EC-GI-10 cells (by 1.3-fold), whereas the overexpression of FGFR3IIIb (FGFR3IIIb) did not significantly affect cell proliferation rates. Cell proliferation was significantly lower (~25%) in EGFP-infected siFGFR3-EC-GI-10 cells (EGFP) than in siFGFR3-EC-GI-10 cells. The parental EC-GI-10 cells were not treated with siRNA (-) and not infected (-) . Cell numbers are the mean ± S.E.M. The experiment was performed with n=6 samples, and repeated thrice. (#, p<0.05 versus the sicontrol cells and *, p<0.05 versus the siFGFR3 cells; t-test, N.S., not significant). (B) Western blotting shows FGFR3 expression levels of parental cells and cells treated with sicontrol, EGFP, siFGFR3, FGFR3IIIb, or FGFR3IIIc. β-actin was expressed equally among the cells. (C) RT-PCR shows that FGF2 was endogenously expressed in parental EC-GI-10 cells. knockdown of endogenous FGFR3 by siRNA reduced cell proliferation beyond that observed in cells treated with sicontrol. FGF2 was endogenously expressed in EC-GI-10 cells, suggesting that the enhanced expression of FGFR3IIIc was beneficial for cancer cell proliferation due to FGF2 binding via an autocrine pathway. In patients with ESCC, FGF2 was expressed in both NCM and ESCC regions, suggesting that the upregulated expression of FGFR3IIIc could trigger carcinogenesis of EC and malignant progression.
In conclusion, FGFR3IIIc has the potential to be not only an early-stage tumor marker but also a molecular target for ESCC therapy. However, the number of EC samples examined here was limited, and further studies are required to validate this conclusion.
